1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aurobindo Pharma Limited

Aurobindo Pharma Limited

AUROPHARMA.BO
Aurobindo Pharma LimitedIN flagBombay Stock Exchange
1,564.65
INR
-21.85
- -
906.75BMarket Cap
Aurobindo Pharma Limited
AUROPHARMA.BO
(Bombay Stock Exchange)

Recent

price

1,564.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
75.16
78.21
99.31
138
206.38
231.92
250.57
276.49
328.14
388.06
419.12
398.79
420.13
489.89
538.38
- -
545.31
Revenue per Share
9.79
-2.12
5.05
20.13
27
34.67
39.33
41.36
40.36
48.56
91.05
45.2
32.9
54.15
59.81
- -
58.32
Basic EPS, GAAP
-6.61
5.6
4.72
11.1
21.2
22.28
56.02
28.67
1.57
50.35
24.84
39.46
-5.69
-19.23
24.11
- -
- -
Free Cash Flow per Basic Share
0.82
0.58
1.16
1.02
2.62
2.3
1.95
3.74
2.49
3
4
4.5
7.5
4.5
0.02
- -
- -
Dividend per Share
24.87
21.89
25.21
41.57
72.11
97.11
138.61
175.3
212.91
257.72
344.67
385.32
410.82
458.41
519.53
- -
- -
Book Value per Share
39.31
36.02
41.18
60.97
79.85
102.82
143.58
165.81
184.07
231.41
321.01
357.73
391.34
439.88
487.42
- -
- -
Tangible Book Value per Share
576
582
582
582
584
584
585
586
586
586
586
586
586
586
583
- -
582
Basic Weighted Avg Shares
43,271
45,537
57,827
80,386
120,430
135,480
146,639
161,992
192,259
227,380
245,579
233,666
246,171
287,045
313,781
333,847
317,122
Sales/Revenue/Turnover
19.06
9.54
12
23.37
19.32
21.01
20.75
20.17
17.19
17.33
18.23
14.12
10.31
15.47
15.79
15.21
15.57
Operating Margin (%)
1,715
2,005
2,487
3,125
3,326
3,924
4,276
5,580
6,680
9,667
10,554
11,265
12,446
15,217
16,494
17,782
16,509
Depreciation Expense
5,634
-1,235
2,939
11,728
15,758
20,251
23,017
24,232
23,647
28,451
53,348
26,482
19,275
31,730
34,859
35,048
33,914
Net Income, GAAP
28.56
- -
22.11
23.72
27.52
26.26
24.82
25.25
23.51
24.03
27.37
21.51
26.21
27.65
31.24
31.47
31.51
Effective Tax Rate (%)
13.02
-2.71
5.08
14.59
13.08
14.95
15.7
14.96
12.3
12.51
21.72
11.33
7.83
11.05
11.11
10.5
10.69
Profit Margin (%)
5,527
3,490
7,059
14,111
22,979
24,541
26,006
35,123
33,117
50,279
91,585
99,667
100,519
120,065
124,801
146,697
- -
Working Capital
5,234
9,646
11,483
12,794
13,111
7,428
1,814
4,512
1,800
2,644
4,347
5,678
9,405
23,874
18,009
10,957
- -
LT Debt
24,540
23,499
26,168
37,758
53,826
68,177
93,740
116,822
138,924
168,248
219,290
245,740
268,518
298,508
326,469
378,828
- -
Total Equity
13.29
- -
9.43
21.17
19.43
19.39
18.69
16.77
13.55
13.6
12.8
9.34
6.21
9.27
8.71
7.95
- -
Return on Invested Capital (%)
19.67
- -
8.27
22.43
22.01
21.57
21.11
18.63
14.38
14.47
22.92
10.42
7.32
10.72
10.56
16.16
57.69
Return on Capital (%)
77.21
-9.13
21.43
60.32
47.54
40.99
33.39
26.36
20.79
20.64
30.23
12.38
8.26
12.46
12.2
23.1
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
64,620
- -
LT Borrowings
- -
15,616
- -
LT Finance Leases
- -
2,392
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
581
- -
Market Capitalization
778,676
675,889
660,118

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
271,625
- -
Cash, Cash Equivalents & STI
- -
81,986
- -
Accounts Receivable, Net
- -
57,459
- -
Inventories
- -
105,437
- -
Total Current Liabilities
- -
146,823
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
64,620
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.04%
11.58%
16.04%
Free Cash Flow
309.91%
5.97%
72.35%
Net Income, GAAP
12.18%
-0.51%
0.54%
Sales/Revenue/Turnover
9.65%
6.56%
6.39%
Total Cash Common Dividend
2,228.34%
4,437.15%
22,246.15%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
67,906
71,507
72,712
74,919
287,045
2025
74,576
76,462
78,932
83,811
313,781
2026
77,918
86,045
87,515
- -
333,847

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9.74
12.83
16.04
- -
54.15
2025
15.69
14
14.56
15.56
59.81
2026
14.2
15.67
15.86
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.5
2025
- -
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -
Similar Companies
Nextleaf Solutions Ltd. (OILS.CN)
Herbal Dispatch Inc. (LUFFF)
Hua Medicine (Shanghai) Ltd. (2552.HK)
Adastra Holdings Ltd. (XTRX.CN)
RPG Life Sciences Limited (RPGLIFE.NS)
China Health Industries Holdings, Inc. (CHHE)
Business
Aurobindo Pharma Limited, headquartered in Hyderabad, India, and founded in 1986, develops, manufactures and markets a broad portfolio of generic pharmaceuticals, active pharmaceutical ingredients (APIs), biosimilars and formulations; core offerings span antibiotics including semi-synthetic penicillins (SSP) and cephalosporins, antiretrovirals (ARVs), cardiovascular products, central nervous system drugs, anti-diabetics, anti-infectives, oncology and hormones, injectables, dermatology, respiratory therapies, gastroenterologicals, peptides, vaccines and sterile products across oral solids, topicals and complex generics. The company operates 29 manufacturing facilities worldwide with vertical integration for formulations and APIs, serving over 150 markets including the US (leading generic player by prescriptions), Europe (top 10 in eight countries), growth markets, Canada, South Africa, Brazil and Japan, holding approvals from regulators such as USFDA, EMA, MHRA UK, Health Canada, ANVISA and PMDA; subsidiaries include Eugia Pharma, CuraTeQ, Aurolife and Theranym, supporting R&D with 876 US ANDA filings (711 approvals), over 4,200 Europe dossiers and strong biosimilar pipeline. Recent developments include Q2 FY26 revenue of Rs 8,286 crore (6.3% YoY growth) driven by US base business, 18% Europe expansion to €243 million, ARV surge and growth markets; biosimilar advancements with European Commission approvals for trastuzumab and three others, UK MHRA nods for bevacizumab and trastuzumab, Phase 3 successes for Prolia and Xolair biosimilars, and filings for immunology/oncology products through FY27; Pen-G facility ramp-up to 15,000 MT under PLI scheme at 40-50% utilization; acquisition integration of Lannett for US injectables, full ownership of GLS Pharma for oncology; new collaboration with global pharma for respiratory products (3-5 year license); six US launches, 13 ANDAs filed, seven approved; capex of $106 million for biosimilars, injectables and China/Europe supply enhancements; net cash position of $170 million.